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Abstract 
Backgroung: Brugada Syndrome (BrS) is an arrhythmogenic disease associated with sudden 
cardiac death (SCD) which seldom manifests or is recognized in childhood.  
Objective: To describe the clinical presentation of pediatric BrS to identify prognostic factors 
for risk stratification, and propose a data-based approach management. 
Methods: We studied 106 patients, under 19 years of age at diagnosis of BrS from 16 
European hospitals. 
Results: At diagnosis, BrS was spontaneous (n=36) or drug-induced (n=70). Mean age was 
11.1±5.7 years and most patients were asymptomatic [family screening (n=67), incidental 
(n=13)] while 15 had experienced syncope, 6 aborted SCD or symptomatic ventricular 
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tachycardia and 5 others symptoms. During follow-up (median: 54 months), 10 patients had 
life-threatening arrhythmias (LTA) including 3 deaths. Six experienced syncope and 4 SVT. 
Fever triggered 27% of LTA events. An ICD was implanted in 22 with major adverse events 
in 41%. Of the 11 patients treated with hydroquinidine, 8 remained asymptomatic. Genetic 
testing was performed in 75 patients and SCN5A rare variants were identified in 58; 15 out of 
32 (47%) tested probands were genotype positive. Nine out of the 10 patients with LTA 
underwent genetic testing and all were genotype positive whereas the 17 SCN5A negative 
patients remained asymptomatic. Spontaneous BrS type 1 ECG (p=0.005) and symptoms at 
diagnosis (p=0.001) were predictors of LTA. Time to the first LTA event was shorter in 
patients with both symptoms at diagnosis and spontaneous BrS type 1 ECG pattern 
(p=0.006). 
Conclusions: Spontaneous type 1 ECG and symptoms at diagnosis are predictors of LTA 
events in the young affected by BrS. The management of BrS should become age-specific 
and prevention of SCD may involve genetic testing, aggressive use of anti-pyretics and 
quinidine with risk-specific consideration for the ICD. 
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Abbreviations List 
aSCD: aborted Sudden Cardiac Death 
BrS: Brugada Syndrome 
DNA: Deoxyribonucleic Acid 
ECG: Electrocardiogram 
EPS: Electrophysiological Study 
HR: Hazard Ratio 
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LTA: Life Threatening Arrhythmias 
ICD: Implantable Cardioverter Defibrillator 
NSVT: Non-Sustained Ventricular Tachycardia 
PCR: Polymerase Chain Reaction 
SCD: Sudden Cardiac Death 
SVT: Supra Ventricular Tachycardia 
VF: Ventricular Fibrillation 
VT: Ventricular Tachycardia 
 
Introduction 
The Brugada Syndrome (BrS) is an arrhythmogenic disease1, with a heterogeneous 
genetic background2–5, usually diagnosed during adulthood. Spontaneous type 1 ECG pattern 
and symptoms are predictive risk factors for life-threatening arrhythmias (LTA) in adults2 
but, given the rarity of BrS in the pediatric population, risk stratification in the young is 
difficult.  
In a Japanese study6 screening elementary school children, only 0.02% of 22,000 
displayed a Brugada type related ECG with only one case of spontaneous type 1 ECG pattern. 
The largest pediatric BrS population studied so far included 30 European children and 
suggested that fever, symptoms and spontaneous type 1 ECG pattern were associated with 
LTA7. Drug-induced BrS in children has been reported8. In the largest series of BrS in 
adulthood2, very few patients were below age 20.  
Our aim was to describe the clinical presentation of BrS below age 19, to identify 
prognostic factors useful to improve risk stratification, and to propose a data-based approach 
to management of this specific population.  
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Methods 
Clinical Data 
Data on 106 patients below age 19 were collected from 16 European tertiary centers; 
29 of them had been described originally in 20077. Inclusion required a type 1 Brugada ECG 
pattern either spontaneously or after challenge with a sodium channel blocker (ajmaline or 
flecainide). Patients displaying only fever-induced Brugada type 1 ECG pattern were 
included in the spontaneous group. The type 1 ECG pattern was defined according to 
consensus guidelines as coved ST-elevation ≥ 0.2mV at its peak in at least one right 
precordial leads (V1 to V3 in the 2nd, 3rd or 4th intercostal spaces)9,10. 
Recorded data included: family history; past medical history; follow-up data from 
hospitalization reports, specialist and general cardiology clinical letters; and direct follow-up 
contact with patients. Syncope was considered of arrhythmic origin when a sudden loss of 
consciousness occurs without any other explanation. 
Twelve-lead ECGs at baseline and, if needed, during drug-challenge, were performed 
according to the guidelines10. The 12-lead ECGs were first analyzed by an expert cardiologist 
in the referring hospital. ECG parameters were then collected at baseline and during drug 
challenge. Either intravenous ajmaline (1mg/kg body weight) or flecainide (2mg/kg body 
weight) were used depending on drug availability at the participating centers. 
A baseline electrophysiological study (EPS) was performed in 22 patients at the 
clinical judgment of the expert cardiologist. A maximum of three ventricular extrastimuli 
with a minimum coupling interval of 200ms were delivered from at least one right ventricular 
site unless VF and/or sustained VT were induced at an earlier stage. 
At diagnosis, patients were considered symptomatic if they had experienced aborted 
SCD (aSCD), ventricular arrhythmias [non-sustained VT (NSVT), VT or VF] or syncope. 
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During follow-up, patients were considered to have a LTA event if sudden death, 
documented VT or VF occurred or if an appropriate ICD shock was documented. 
Genetic Analysis 
Genetic testing was conducted according to guidelines and was approved by local 
ethics committees for research or regular clinical purposes. Informed written consent was 
obtained either from the parents or the patient (if above age 18). Genomic DNA was 
extracted from peripheral blood leukocytes using standard protocols. All exons of SCN5A 
were amplified by PCR. PCR products were screened for an SCN5A mutation using 
denaturing high-performance liquid chromatography and/or direct DNA sequencing. In 
probands, all exons of SCN5A were screened whereas only the specific exon was sequenced 
if a rare variant had been identified previously in the family. 
Statistical Analysis 
Data were analyzed with SAS packages (SAS Institute Inc., Cary, NC). The Chi2 or 
Fisher exact tests were used to compare categorical variables. The t-test, Mann-Whitney, 
Kruskall Wallis tests were performed to test for differences in continuous parameters. ECG 
baseline data were corrected for age using linear regression model. Mean data were presented 
with standard deviation. Time data were presented with median [1st-3rd quartile]. Time from 
diagnosis to the first event was analyzed with Cox proportional hazards model. Hazards ratios 
(HR), confidence intervals (CI) and p-values were calculated in univariate analysis. Log-rank 
p-value was used if Cox model was not relevant. Multivariate analysis was adjusted on 
variable with p-value<0.15 in univariate analysis using Cox model. Survival curves were 
plotted by the Kaplan Meier method. A p-value <0.05 was considered statistically significant. 
The authors had full access to and take full responsibility for the integrity of the data. 
All authors have read and agree to the manuscript as written.  
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Results 
Population 
A total of 106 patients from 91 families were enrolled. The mean age at diagnosis was 
11.1±5.7 years with a median [1st-3rd quartiles] follow-up of 54 [15-99] months which was 
longer (117 [87-142]; p<0.0001) among the 29 children described in 20077. Forty-six (43%) 
had a familial history of SCD. Sixty-seven children were diagnosed below 15 years of age, 
including 35 below age 8. Fifty-eight (55%) were male. No gender difference was observed 
under 15 years of age (sex ratio=1.03; 34M/33F) but there was a trend for males to be more 
common above age 15 (sex ratio=1.60; 24M/15F [p=0.32]). 
Symptoms (supplemental material; Table 2): Twenty-one (20%) patients were considered 
symptomatic at diagnosis: 15 (14%) syncope; 4 aSCD; and 2 with VT. They were 
predominantly male (sex ratio=2.5). Five out of the 6 patients with aSCD or VT were under 5 
years of age. Most patients were completely asymptomatic at diagnosis (67 [63%] diagnosed 
during familial screening and 13 [12%] incidentally). In addition, 2 patients who presented 
with supra-ventricular tachycardia (SVT) and 3 who experienced subjective symptoms 
(presyncope or palpitations) were considered asymptomatic at diagnosis for the purposes of 
our survival analyses. 
ECG findings at diagnosis (supplemental material; Table 3): Thirty-six (34%) patients 
presented with a spontaneous type 1 ECG pattern, of whom 14 (39%) were symptomatic at 
diagnosis. Among these 36 patients, 7 displayed the type 1 ECG pattern only during a fever 
episode (Figure 1). The 70 (66%) remaining patients presented with a type 1 pattern after 
provocation testing, of whom only 7 (10%) were symptomatic at diagnosis. Males were more 
common in the spontaneous group (sex ratio= 2.6) whereas females were more common in 
the drug-induced group (sex ratio=0.84 [p=0.013]). A spontaneous type 1 ECG pattern was 
significantly associated with male gender (p=0.013) and symptoms at diagnosis (p=0.0007). 
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Genetics (Table 1): Seventy-five patients, belonging to 62 families, underwent SCN5A 
analysis. Thirty-two (43%) were pediatric probands in whom all exons were tested: fifteen 
(47%) tested positive. In 43 patients, direct sequencing was performed to detect the SCN5A 
mutation identified in the family. Overall 58/75 (77%) were genotype positive (Supplemental 
material Table 1). 
Drug Challenge/EPS 
Drug challenges were performed in 70 (66%) patients with ajmaline (n= 42) or 
flecainide (n=27; unknown=1). Median ages at challenges were 14.3±3.7 years for ajmaline 
and 13.4±4.5 years for flecainide (p=0.38). Two patients (15.6 and 16.7 years of age both 
SCN5A positive) developed NSVT for which no specific therapy was needed. No other 
adverse events were observed. ECG parameters at baseline, before and during drug challenge 
are summarized in Supplemental material; Table 4. EPS were performed in 22 (21%) 
patients, nine of whom were symptomatic at diagnosis, and were reported as “positive” or VF 
inducible in 9 (41%). 
Treatment 
An ICD was implanted in 22 (21%) patients, of whom 18 received an endocardial 
ICD and 3 a system with an epicardial ventricular lead and a subcutaneous or intercostal coil. 
Eighteen ICDs were implanted as primary prevention whilst four patients were implanted 
after an aSCD or VT. Four pacemakers were implanted in SCN5A positive patients with 
symptomatic sinus node dysfunction. 
Hydroquinidine was started in 11 (10%) patients: 9 (8%) with a spontaneous type 1 
ECG pattern; and 8 following arrhythmic events. Blood concentrations of quinidine were 
only available in 3 patients, and in the therapeutic range as defined by the local laboratory. 
No side effects were reported for hydroquinidine. 
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Follow-up 
During a median follow-up of 54 [15-99] months 10 (9%) patients had 15 LTA 
events. Fever was associated with 4 (27%) of these events. Three patients died, 5 suffered VT 
and 2 both VT and VF. The mean age at diagnosis was 6.5±7.0 years with a median follow-
up of 42 [6-73] months (Table 2). Two had a drug-induced type 1 ECG pattern at diagnosis. 
Seven (70%) were symptomatic at diagnosis [aSCD (n=3), syncope (n=3) and VT (n=1)]. 
Nine (90%) carried a SCN5A mutation.  
A LTA during follow-up was experienced by 2 out of 9 (22%) patients with a positive 
EPS, and by 1 of 13(8%) patients who had a negative EPS (p=0.85). Two (11%) from the 18 
primary prevention ICD patients had appropriate ICD shocks. Eight (73%) of the 11 patients 
receiving hydroquinidine remained free from LTA after initiation of therapy. 
Another 6 (6%) were syncopal without documented arrhythmia. Four (4%) had SVT: 
two atrial flutter treated by catheter ablation and two atrial tachycardia. A flow-chart of 
clinical presentation and follow-up is presented in Figure 2 and a clinical description of LTA 
events during follow-up can be found in supplementary data. 
ICD complications 
Serious ICD-related complications occurred in 9 (41%) of the 22 patients including 
lead failures (n=4), inappropriate shocks (n=4), endocarditis with re-implantation (n=2) and 
hemothorax (n=1). Two patients had both lead failure and inappropriate shocks or 
endocarditis. All complications were related to endocardial devices except the hemothorax, 
which appeared in the early post-operative period after epicardial ventricular lead 
implantation. 
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Predictive factors for LTA  
Nine of the 10 patients who experienced LTA were SCN5A carriers (Table 3), the 
remaining patient having not undergone genetic screening. LTA did not occur in the 17 
genotype-negative patients.  
In a univariate analysis, a spontaneous type 1 ECG pattern (HR=9.1; CI [1.9-42.96]; 
p=0.005) and symptoms at diagnosis (HR=9.65; CI [2.48-37.49]; p=0.001) were predictive 
of a shorter time to first LTA event whereas a family history of SCD (p=0.28), gender 
(p=0.72) and positive SCN5A (p=0.08) genotype were not (Table 3). Due to the low number 
of patients undergoing EPS (n=22), no statistical difference could be demonstrated between 
patients with positive or negative EPS. The presence of an ICD (p=0.003) was associated 
with LTA events but denoted an already high-risk subgroup and could not be considered a 
predictive factor.  
The Figure 3 shows the time to first LTA event in the following groups: symptomatic 
at diagnosis (S+); asymptomatic at diagnosis (S-); spontaneous type 1 ECG pattern (ECG+) 
and drug induced type 1 ECG pattern (ECG-) (global p-value=0.006). 
Following univariate analysis, we divided patients in different groups (Table 3): 
group S+/ECG+ (n=14); group S+/ECG- (n=7); group S-/ECG+ (n=22) and group S-/ECG- 
(n=63). These four groups showed differences in time to first LTA event (global p-
value=0.006; Figure 4). Group S+/ECG+ had a shorter time to first LTA event compared to 
group S-/ECG- (HR=31; CI [3.8-265]; p=0.001). No difference was found when making 
other comparisons. In a second univariate analysis, we divided the spontaneous type 1 ECG 
pattern group into two groups: type 1 ECG pattern only with fever and other spontaneous 
type 1 ECG patterns. Whilst there was no difference between them in time to first LTA event 
(p=0.08) both of these groups showed a shorter time to LTA event compared to the drug-
induced group (global p-value=0.002).  
11 
 
Multivariate analyses were adjusted for age and ICD. In a first multivariate analysis, a 
spontaneous type 1 ECG pattern (HR=5.9; CI [1.2-30.4]; p=0.03) and symptoms at diagnosis 
(HR=4.7; CI [1.2-19.4]; p=0.03) were predictive of LTA events. 
In a second multivariate analysis of time to first LTA event, a difference was found 
between the four groups (global p-value=0.006). Group S+/ECG+ had a shorter time to first 
LTA event compared to group S-/ECG- (HR=28.9; CI [3.4-242.6]; p=0.002). No difference 
was found when making other comparisons. 
 
Discussion 
Three of the 8 patients reported in the first description of BrS1 were under 8 years of 
age. However, few data are available on the natural history in children7,8,11 and the 
management of this special population has been inconsistent12. This study represents the 
largest series of pediatric BrS patients described as yet. As in the adult population, we show 
that a spontaneous type 1 ECG pattern and symptoms at diagnosis are predictive of a shorter 
time to first LTA event. 
Brugada syndrome in children 
 Our cohort showed no significant gender difference in BrS carriers up to age 15. A 
trend in male predominance then develops after this age and presumably continues into 
adulthood. This reflects the likely role of androgens in BrS, which may involve circadian 
rhythm of testosterone release13,14.  
More than half of our population was diagnosed during family screening using 
sodium channel blocker challenge. Recently, Conte et al8 reported their experience of 40 
positive sodium channel blocker challenges in children below age 12. During a follow-up of 
83 months, only 1 arrhythmic event occurred whereas 10% of tests were complicated by 
arrhythmia. In our experience this risk was lower (2/70; 2 NSVT in 2 SCN5A carriers among 
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70 tests). Their use at a very young age appears questionable, however, due to the low risk of 
LTA in asymptomatic patients without a spontaneous type 1 ECG pattern and the potential 
arrhythmogenic risk and psychological impact of provocation tests15. 
Fever is known to associate with arrhythmic events16 and unmask the type 1 ECG 
pattern17, which is 20 times more common in febrile patients18. In this study, fever triggered 
up to a quarter of all arrhythmic events. Dumaine et al19 have demonstrated a diminished 
inward current through mutant cardiac sodium channels due to changes in biophysical 
properties at higher temperatures. Despite this evidence the mechanism of fever-induced BrS 
remains incompletely understood. Early childhood might be a period of high risk because of 
the frequent occurrence of fever. Even if the rate of arrhythmic events during fever is 
unpredictable we still advise aggressive treatment with antipyretics. We also advise the 
recording of a standard ECG when BrS children are admitted to hospital with a fever. If the 
ECG is abnormal, they should be monitored until their ECG returns to its usual baseline. 
We chose to include in the same group patients who displayed a type 1 ECG pattern 
spontaneously or only with fever due to a lack of power resulting from low numbers. These 2 
subgroups may not, however, have the same arrhythmic risk and need to be evaluated 
separately in a larger cohort. 
SCN5A mutation status and its implications 
SCN5A mutations were found in a higher proportion of patients than expected. In 
particular we found a 47% prevalence of SCN5A mutations in index patients, more than 
double that seen in adults with BrS20. Given the important role of conduction defects and 
increasing age in the pathophysiology of the disease21,22, one can speculate that the 
impairment of conduction associated with SCN5A mutations facilitates the development of 
BrS in the pediatric population. 
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All 9 genotyped patients who experienced LTA had a SCN5A mutation, but 7 also 
displayed a spontaneous type 1 ECG pattern. By contrast, none of the 17 genotype-negative 
patients, suffered a LTA event. Thus, in our cohort the presence of a SCN5A mutation may be 
necessary, but is insufficient on its own for the development of LTA23,24. These results 
should, however, be treated cautiously due to the low number of patients and the high 
prevalence of SCN5A mutations. Further studies are needed to assess if the presence or 
absence of a SCN5A mutation may be useful for risk assessment in the young. 
Therapy in the young 
An ICD was implanted in 22 patients with a high subsequent complication rate (41%). 
This high risk for adverse events is probably compounded in this young population by rapid 
physical growth and a high level of physical activity. The incidence may be decreased by 
using the subcutaneous ICD or subcutaneous coil25. In a small and selected group of 
paediatric patients, Pettit et al.26 suggests a lower incidence of inappropriate shocks or 
reoperations with a subcutaneous ICD compared to a transvenous ICD.  
Hydroquinidine may be an attractive alternative, and most of our patients treated with 
hydroquinidine remained asymptomatic. In the adult population hydroquinidine tends to be a 
safe alternative28,29 but given the small number of patients and the relatively short follow-up 
in this cohort, larger-scale studies are needed. 
Nonetheless we advise consideration of ICD implantation or quinidine therapy in 
patients with a spontaneous type 1 ECG pattern and symptoms. The prognosis of the 
asymptomatic patients as well as patients presented with a drug-induced type 1 ECG pattern 
seems to be good. Thus those with drug-induced type 1 ECG pattern without symptoms 
should be only considered for clinical follow-up. There is more uncertainty when symptoms 
or a spontaneous type 1 ECG pattern are present. Therapy should then be discussed on a case 
by case basis. Fig. 5 shows a flow-chart of our recommended approach.  
14 
 
Conclusion 
A spontaneous type 1 ECG pattern and symptoms at diagnosis are predictive of a 
shorter time to first LTA event in the young. The risk of LTA is especially high in patients 
with both symptoms and a spontaneous type 1 ECG. These patients need to be considered for 
ICD implantation and/or chronic therapy with quinidine or hydroquinidine. Patients with a 
drug-induced type 1 ECG and without symptoms have a low arrhythmic risk and a good 
prognosis. In this population, regular clinical follow-up without specific treatment seems to 
be sufficient. 
In asymptomatic patients with a spontaneous type 1 ECG pattern and in symptomatic 
patients without a spontaneous pattern, the risk appears to be relatively low and the decision 
to eventually implant an ICD or to introduce hydroquinidine therapy needs to be discussed 
case by case in highly experienced centers. The absence of a SCN5A mutation may then 
denote a lower risk of events and might be taken into account. Fever remains the most 
important trigger for LTA events and parents need to be advised to treat it aggressively with 
anti-pyretics. 
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Clinical Perspectives 
This study provides evidence-based indications useful for the cardiologist who may face 
difficult management decisions when dealing with a Brugada syndrome (BrS) in children. As 
suspected, a spontaneous type 1 ECG pattern and symptoms at diagnosis are predictive of 
life-threatening arrhythmia (LTA) events in children affected by BrS. Patients with both are 
at the high risk and need to be considered for ICD implantation. Asymptomatic patients with 
a drug-induced type 1 ECG pattern have a good prognosis and regular clinical follow-up 
seems to be sufficient. Others clinical situations need to be considered on a case by case basis 
in experienced centers and there may be a role for hydroquinidine as well as aggressive anti-
pyretic therapy. SCN5A negative genotype may be associated with less LTA events, but this 
remains to be proven. Given the rarity of BrS in the young, larger studies are required to 
confirm and then apply these results in daily clinical practice. As undertaken for BrS in 
adults, specialized centers need to collaborate to evaluate larger cohorts in the future. 
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Figures Titles and Legends 
Figure 1: 12-lead ECG at baseline (up) and during a febrile episode (down) in a 2.5 years old 
female. During fever, ST-segment elevation occurred with coved-type morphology in lead V1 
and V2, leading to diagnosis of BrS. 
Figure 2: Flow-chart of patients clinical characteristics and events during follow-up. 
Figure 3: Kaplan-Meier curves of LTA events during follow-up in four different groups 
(global p-value =0.006). Patients with spontaneous type 1 ECG pattern (ECG+) OR 
symptoms (S+) at diagnosis had a shorter time to first LTA event. 
Figure 4: Kaplan-Meier curves of LTA events during follow-up in four different groups 
(global p-value =0.006). Patients with spontaneous type 1 ECG pattern (ECG+) AND 
symptoms (S+) at diagnosis had a shorter time to first LTA event. 
Figure 5: Flow-chart for management of the young with a known BrS in the family. 
Tables 
Table 1: Patients Characteristics According to their SCN5A status (n=75) 
Positive (n=58) Negative (n=17) p-value 
Male, n (%) 33 (57) 10 (59) 0.78 
Age at diagnosis, y 9.8 ± 6.0 12.7 ± 4.4 0.02 
Symptoms at diagnosis, n (%) 10 (17) 3 (18) 1 
Follow-up, mo 63 [20-102] 66 [24-117] 0.70 
LTA events during follow-up, n (%) 9 (16) 0 (0) 0,08* 
Probands, n (%) 15 (26) 16 (94) <0.0001 
Spontaneous Type 1 ECG Pattern 20 (34) 8 (47) 0.40 
Familial history of SCD, n (%) 25 (43) 6 (35) 0.78 
Baseline ECG parameters 
Heart Rate (bpm) 83 ± 23 85 ± 20 0.06 
PR (ms) 171 ± 34 155 ± 20 0.01 
QRS (ms) 103 ± 16 94 ± 14 0.34 
QTc Bazett (ms) 431 ± 33 402 ± 34 0.15 
Maximum ST Elevation (mm) 1.8 ± 2.0 2.7 ± 2.6 0.03 
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ICD, n (%) 14 (24) 3 (18) 0.75 
Quinidine, n (%) 8 (14) 2 (12) 0.83 
EPS performed, n (%) 14 (24) 6 (35) 0.47 
positive, n=20 7 (12) 1 (6) 0.32 
* log-rank p-value  
 
Table 2: Patients Characteristics According to LTA Events during Follow-up and Predictive 
Factors for LTA in Univariate Analysis (n=106) 
LTA events (n=10) No LTA event (n=96) HR [CI 95%] p-value 
Male, n (%) 6 (60) 52 (54) 0.79 [0.22-2.81] 0.72 
Age at diagnosis, y 6.5 ± 7.0 11.6 ± 5.4 0.86 [0.76-0.96] 0.009 
Age at diagnosis < 15y, n (%) 7 (70) 60 (62) 0.74 [0.19-2.89] 0.66 
Follow-up, mo 42 [6-73] 55 [15-103] - - 
Symptoms at diagnosis, n (%) 7 (70) 14 (15) 9.65 [2.481-37.49] 0.001 
Spontaneous Type 1 ECG Pattern (%) 8 (80) 28 (29) 9.1 [1.9-42.96] 0.005 
Familial history of SCD, n (%) 3 (30) 43 (45) 2.12 [0.55-8.21] 0.28 
ICD, n (%) 5 (50) 17 (18) 3.85 [1.11-13.36] 0.003 
SCN5A mutations, n (%) 9 (90) 49 (51) - 0.08* 
* log-rank p-value     
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Table 3: Patients Characteristics According to Clinical Presentation and Type 1 ECG 
(n=106) 
Symptomatic & 
spontaneous 
Symptomatic & 
drug induced 
Asymptomatic & 
spontaneous 
Asymptomatic & 
drug induced p-value 
Group S+/E+ (n=14) Group S+/E- (n=7) Group S-/E+ (n=22) Group S-/E- (n=63) 
Male, n (%) 10 (71) 5 (71) 16 (73) 27 (43) 0.03 
Age at diagnosis, y 6.0 ± 5.4 14.3 ± 5.6 7.5 ± 5.5 13.1 ± 4.6 < 0.04 
Follow-up, mo 70 [5-125] 91 [23-138] 46 [8-106] 47 [18-93] 0.83 
LTA event during follow-up, n (%) 6 (43) 1 (14) 2 (9) 1 (2) 0.006* 
Familial history of SCD, n (%) 2 (14) 4 (57) 7 (32) 33 (52) 0.041 
Baseline ECG parameters     
Heart Rate (bpm) 89 ± 25 66 ± 13 91 ± 22 78 ± 18 0.22 
PR (ms) 176 ± 25 174 ± 25 161 ± 30 162 ± 33 0.38 
QRS (ms) 108 ± 19 99 ± 19 105 ± 22 96 ± 14 0.10 
QTc Bazett (ms) 423 ± 29 400 ± 41 423 ± 29 420 ± 36 0.48 
Maximum ST Elevation (mm) 3.8 ± 2.1 1.9 ± 1.2 3.9 ± 2.2 0.6 ± 0.9 < 0.001 
ICD, n (%) 5 (36) 3 (43) 5 (23) 9 (14) 0.13 
Quinidine, n (%) 5 (36) 0 4 (18) 2 (3) 0.003 
Genetic test performed, n (%) 11 (79) 2 (29) 17 (77) 45 (71) 0.03 
SCN5A mutations, n (%) 9 (64) 1 (14) 11 (50) 37 (59) 0.15 
EPS performed, n (%) 7 (50) 2 (29) 3 (14) 10 (16) 0.25 
positive, n=22 2 (14) 1 (14) 1 (5) 5 (8) 0.91 
* p-value calculated by cox model  
Figures 
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S+/ECG+ = Symptomatic & Spontaneous Type 1  14 6 6 6 3 2 
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S-/ECG+ = Asymptomatic & Spontaneous Type 1  22 22 13 11 6 3 
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Genetic testing‡ 
Every year* 
Control ECG + 12 leads 24h Holter  
Genetic testing if genotype positive relatives 
Spontaneous type 1 ECG pattern 
Yes 
No 
Prone to BrS 
Every 5 years* 
ECG + 12 leads 24h Holter 
Every 2-3 years * 
ECG + 12 leads 24h Holter 
Age 15 
Pharmacologic 
challenge§ 
*Or earlier review at physician discretion 
† Potentially cardiac arrhythmias related 
symptoms, excluding vaso-vagal syncope 
‡ If allowed by current local regulations 
§Ajmaline 1mg/Kg or flecaïnide 2mg/Kg 
 
 
 
Lifestyle recommendations, including drug 
avoidance and fever precautions should be 
considered for all patients 
Not prone to BrS 
Negative 
Symptoms† 
Pharmacologic  
challenge§ 
Yes 
Consider if no 
 contra-indication 
Every year* 
ECG +12 leads 24h Holter  
Consider quinidine 
No 
Management of the Young with a known BrS in the Family 
No 
Positive 
Yes 
Negative Positive 
Pathogenic variant in 
first degree relatives 
Every 2-3 years * 
ECG + 12 leads 24h Holter 
Symptoms 
Consider ICD or quinidine 
